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Abstract 
 
Introduction: Obesity is growing epidemic and risk factor for the development of breast 
cancer. Studies conducted to date have not shown a consistent relationship between 
weight loss and the risk of cancer development however there has been an increasing 
focus on calorie restriction diets and intermittent energy restriction diets and their impact 
on breast cancer progression. We aimed to improve the understanding of how different 
energy restriction diets affect obesity-associated, tumor-promoting inflammation in breast 
cancer and the role of gut microbiota in this inflammation. 
 
Methods: Female C57BL/6 mice were randomized onto control diet (n = 20) and diet 
induced obesity diet (n = 80). At week 15, the diet induced obesity (DIO) group was 
randomized to four different groups: mice that remained on DIO diet, a high-carb calorie 
restriction diet, a low-carb calorie restriction diet, and an intermittent energy restriction 
diet. At week 25, mice were injected with a mixture of E0771 cells. Three to four weeks 
later, a final sacrifice was performed. Serum and tissue samples were collected and 
analyzed to determine significant differences in body composition, tumor weight and 
size, serum hormone and adipokine levels, and local mRNA expression of cytokines and 
proteins.  
 
Results: The obese group had significantly greater body weight, visceral white adipose 
tissue, and more severe tumor outcomes than the Control and the calorie restriction 
groups (High Carb Calorie Restriction, Low Carb Calorie Restriction, and Intermittent 
Energy Restriction). Additionally, the obese group had significant dysfunctional changes 
in serum hormones and adipokines and greater expression of pro-inflammatory cytokines 
than anti-inflammatory cytokine. The calorie restriction groups reversed this. Lastly, the 
obese group presented with a more permeable gut epithelium and lower expression of 
colonic occludin that maintains gut impermeability. This led to increased serum 
lipopolysaccharides in the obese group. There was little to no reversal of these changes in 
the calorie restriction groups.  
 
Conclusion: Obesity induced significant systemic and local changes in the mice that 
resulted in more severe tumors. The calorie restriction diets were able to reverse these 
changes (except for changes in the gut epithelium and serum lipopolysaccharide levels) 
and had less severe mammary tumors.  
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Introduction 
 
Obesity  
Obesity is growing epidemic and health concern in the United States (US). 
According to the Centers for Disease Control (CDC) more than one-third of US adults are 
obese (based off of population data collected between 2011 and 2012)1. The National 
Institutes of Health (NIH) echoes these findings, reporting that more than two-thirds of 
US adults are either overweight or obese2.  
Multiple factors contribute to the development of obesity, including 
socioeconomic status, education level, age, sex, race/ethnicity, eating and physical 
activity habits, and genetic heritability. Obesity is implicated in an increased risk of 
cardiovascular disease, type II diabetes, and several types of cancers, including 
esophageal, pancreatic, colorectal, and breast3.  While the direct mechanisms for how 
obesity increases the risk of cancer development are still being studied, several 
possibilities have emerged, including dysregulated leptin and adiponectin secretion, high 
levels of insulin-like growth factor 1 (IGF-1), and hyperinsulinemia. High levels of IGF-
1, a hormone that is anti-apoptotic and promotes cell growth4, have been consistently 
seen in obese individuals4 and may account for their increased risk of tumor 
development. Additionally, insulin resistance and subsequent hyperinsulinemia, found in 
obese individuals, have been associated with increased inflammation, and growth5; all of 
which can contribute to increased tumor development.   
Cancer 
 The American Society of Clinical Oncology has projected that cancer will soon 
outpace heart disease as the leading killer of individuals in all age groups in the US6,7. 
Cancers arise when there are genetic dysfunctions within cells that promote uncontrolled 
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cell growth. In women, who make up about half US population, breast cancer is the 
second most common type of cancer. One out of every eight women in the US is 
expected to develop invasive breast cancer during her lifetime8. Although being 
overweight or obese is a risk factor for breast cancer development9, the relationship 
between the two is complex and still under investigation.  
 Breast cancer results from unregulated cell growth within the breast tissue, and 
the most common form is ductal carcinoma (cancer within the ducts of breast tissue). 
There are four major molecular subtypes of breast cancer: luminal A, luminal B, triple 
negative, and HER2 type. The triple negative subtype tends to be more aggressive than 
luminal A and B and has a poor prognosis. This subtype is also negative in three different 
receptor types: estrogen receptor, progesterone receptor, and HER210. 
 Inflammation may be an important mechanism linking obesity to cancer 
development. In obesity, increased adipose tissue can lead to secretion of increased levels 
of adipokines, cytokines, and chemo-attractants that promote growth and inflammation11. 
Inflammatory cytokines like interleukin 6 (IL-6), interleukin 1 beta (IL-1β), and tumor 
necrosis factor alpha (TNF-α) are overexpressed in the adipose tissue of obese 
individuals12,13. These cytokines can also be found in the local tumor environment and 
have been shown to drive acute inflammation, promote cell growth, and prevent 
apoptosis12,13. Increased inflammation in the local tumor environment or changes in other 
tissue types that promote inflammation are potential mechanisms by which obesity can 
increase breast cancer development.  
Gut and Microenvironment 
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In addition to other systemic changes, obesity is known to induce changes in the 
gut microenvironment and increased permeability of gut epithelium14. Although the role 
of these microorganisms is not completely understood, the gut microbiota are thought to 
provide additional metabolic functions including: fermentation of complex 
polysaccharides, provision of additional energy-containing metabolites for the host to 
utilize, metabolism of bile acids, and metabolism of other molecules15 in the gut in 
cooperation with the host via “crosstalk”. This complex relationship between the gut 
microbiota and the host shows their interdependence. Therefore, severe systemic changes 
in the host, such as those that occur during obesity, can lead to changes in gut integrity 
and the gut microenvironment16. 
It is known that gut microbiota change in response to the state of the host, whether 
they are lean or obese17. Transplantation of gut microbiota from an obese mouse into a 
germ-free mouse results in significant weight gain in comparison to germ-free mice 
transplanted with microbiota from a lean mouse18. This demonstrates that an obesogenic 
diet can induce changes in the gut microenvironment that further promote weight gain. 
In obese individuals, the epithelial barrier function is impaired and allows for the 
translocation of certain molecules, such as lipopolysaccharides (LPS), into blood. LPS 
has been shown to induce inflammation and promote tumor growth19,20 and could 
contribute to tumor-promoting inflammation in obese individuals. While the exact 
mechanism for how LPS diffuses into the circulation and drives tumor promotion is still 
under investigation, it has been shown that LPS can elicit a strong immune response and 
can be important in mediating chronic inflammation20. This increased intestinal 
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permeability and increased serum LPS may contribute to systemic inflammation in 
obesity that promotes tumor development.   
Interventions to Combat Obesity 
Studies conducted to date have not shown a consistent relationship between 
weight loss and the risk of cancer development. While some studies support that 
intentional weight loss does reduce the incidence of obesity-related cancers21,22,23, others 
have shown no benefit. The International Agency for Research on Cancer (IARC) 
reported that avoiding weight gain has been shown to prevent cancer risk, but there was 
insufficient evidence to support the hypothesis that intentional weight loss reduces cancer 
risk24. Determining a direct association between intentional weight loss and cancer risk is 
difficult since few individuals maintain significant weight loss for a long period of time. 
Therefore, protective benefits of intentional weight loss in large populations are hard to 
study. However, calorie restriction (CR), a method for reducing weight, has been found 
to be protective against cancer development in mice25,26.  
Diet and exercise interventions have been proposed and developed to combat and 
reverse obesity by primarily restricting calories. Such diet interventions/diet plans 
include: the Atkins diet, the Zone diet, the Ornish diet, the South Beach diet, and many 
others. These diets differ primarily in macronutrient distribution. However, a consistent 
limitation with all diet interventions is long-term adherence. An individual may lose 
weight initially, but due to the rigorous nature of the diet plan and whether it properly 
meets the needs of the individual’s behavioral, cultural, and other personal beliefs, long-
term adherence may not be actualized. Therefore, the individual is likely to regain the 
weight they lost and potentially can gain more than their starting weight27,28.  
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The diet plans mentioned above are considered to be chronic or daily CR diets. 
While these daily CR diets have been shown to reverse the systemic perturbations 
induced by obesity29, there has been an increasing focus on intermittent energy-restriction 
(IER) diets, where the individual has repeated sessions of severe CR interspersed with 
low-to-moderate CR. This type of plan has been proposed as an alternative option to 
chronic CR since it is more flexible and may lead to better health outcome, such as a 
reduction in the risk of several types of cancers including breast30. Harvie et al (2013) 
compared an IER Mediterranean type diet with a daily energy restricted (DER) 
Mediterranean type diet in adult women with an increased risk of breast cancer but no 
prior breast cancer. IER diets required a 70% CR two days per week while the diet on the 
remaining five days met their estimated energy requirements. Both the IER and DER 
diets restricted energy intake by 25% on average. The authors found that the IER diet 
resulted in improved insulin sensitivity, reduced insulin resistance, and improved fat loss 
when compared to the DER group. This study and several others have shown that IER 
diets have superior short-term effects on metabolic factors when compared to DER diets 
and can be an alternative to more popular dieting plans30,31,32, but long-term studies 
would be needed to determine their impact on breast cancer risk. 
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Goal and Hypotheses 
Goal:  
To improve the understanding of how different energy restriction diets affect obesity-
associated, tumor-promoting inflammation in breast cancer and the role of gut microbiota 
in this inflammation. 
• Aim 1: Determine the impact of different energy diets on body weights, body 
composition, and serum metabolic hormones. 
• Aim 2: Determine the impact of different energy diets on tissue inflammation 
markers by measuring serum marker levels and localized, pro-inflammatory gene 
expression in mammary fat pads. 
• Aim 3:	Characterize the impact of these diets on gut microbiota composition. 
 
Hypotheses: 
• Aim 1: Compared to control, DIO will promote greater levels of serum metabolic 
hormones (but lower levels of adiponectin). LCCR, HCCR, and IER will reverse 
the effects of DIO to some degree. 
• Aim 2: Compared to control, DIO will promote greater levels of tissue 
inflammation markers (but lower levels of IL-10). LCCR and IER will show 
greater reversal of DIO effects when compared to HCCR. 
• Aim 3: Compared to control, DIO will promote significant changes, reducing 
diversity of divisions of the gut bacteria. LCCR and IER will show moderate 
changes with a more diverse microenvironment compared to HCCR.  
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Methods 
Female C57BL/6 mice were randomized to receive a control diet (10% kcal from 
fat, n=20) or diet-induced obesity (DIO) diet (60% kcal from fat, n=80) and housed two 
per cage. After 15 weeks on the control or DIO diet, the control mice continued on the 
same diet, and the DIO mice were randomized to continue on the DIO regimen (n=20) or 
change to one of three CR diets (n=20/group): high carb 30% calorie restriction (HCCR), 
low carb 30% calorie restriction (LCCR), or intermittent energy calorie restriction (IER) 
for a further 10 weeks (resulting in a total of five groups: control, DIO, HCCR, LCCR, 
IER). Five mice/group were sacrificed at week 25 of the study (interim sac), while the 
remaining mice in each group (n=15) were injected with a solution of E0771 mammary 
tumor cells into the 4th mammary fat pad. These mice were monitored for tumor 
progression at least three days/week and tumor sizes were estimated using a caliper 
biweekly. Approximately 3-4 weeks after injection of E0771 cells, mice were sacrificed 
by CO2 euthanasia plus cervical dislocation. At necropsy, mammary tumors, liver tissue, 
lung tissue, brain tissue, colon, blood, visceral white adipose tissue (VWAT), 4th and 9th 
mammary fat pads (MFP), and potential tumor metastases from the body cavity were 
collected. Weekly body weights and food intake were measured and recorded for the 
duration of the study. Stool was collected every five weeks through the end of study.  
Diet type: 
Table 1 describes the composition of the diets. The HCCR and LCCR diets 
restricted daily calories by 30% compared to ad libitum control. The IER diet restricted 
calories by 70% for two nonconsecutive days per week and 14% for the remaining five 
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days. The average daily kilocalorie intake and macronutrient distribution for IER was 
equivalent to LCCR.  
Diet Type Percent 
Carbohydrate 
Composition 
Percent Fat 
Composition 
Percent Protein 
Composition 
Percent Calorie 
Restriction 
Control 70 10 20 0 
DIO 35 45 20 0 
HCCR 57 14 29 30 
LCCR 41 30 29 30 
IER 41 30 29 70 (2 days), 14 
(5 days) 
Table 1: Percent kCal distribution of diets 
Weight and Tumor analysis:  
Body composition/percent fat was determined using quantitative magnetic 
resonance. VWAT was weighed after removal during necropsy. Mammary tumors were 
weighed after removal and the dimensions measured in order to determine tumor volume.  
Stool analysis: 
 Stool was collected in cryovials and stored at -80º C. Stool will be analyzed by 
16S rRNA gene sequencing to determine gut microbiota diversity.  
Serum analyses:  
Blood was collected in 0.5 mL microcentrifuge tubes from mice at the time of 
sacrifice. After allowing the samples to clot for at least 30 minutes at room temperature, 
samples were centrifuged and sera collected and stored at -80º C. Serum levels of 
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hormones, adipokines, and cytokines were analyzed by Bio-Plex Multiplex Immunoassay 
(Bio-Rad), as per the manufacturer’s protocol for these assays. 
mRNA expression levels (occludin, tight junction proteins in murine colon tissue): 
 During necropsy, colon tissue was harvested and frozen at -80C. RNA was isolated 
from colon tissue using TRIzol reagent (ThermoFisher), and cDNA was synthesized via 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Relative mRNA 
levels of occludin and ZO-1 (tight junction protein 1) were quantified by real-time qPCR 
using Taqman™ Gene Expression Assays and a ViiA™ 7 Real-Time PCR System 
(Applied Biosystems). Relative mRNA levels of IL-6, IL-1β, IL-10, and TNF-α were 
measured in the 9th MFP, distal to tumor, using the same methods. 
Serum Endotoxin 
A Pierce™ LAL Chromogenic Endotoxin Quantitation Kit (ThermoFisher Scientific) was 
used to quantify serum endotoxin levels. 
Statistical analysis: 
A one-way ANOVA test (using the program GraphPad Prism 6) was used to 
determine the significant differences between the five groups, at a significance level of p 
< 0.05. 
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Results 
Body Weight, Percent Body Fat, and VWAT Analysis: 
The DIO group weighed significantly more than Control and the three CR groups 
(all p values < 0.0001). Mean body weights in the CR groups were significantly less than 
Control (all p values < 0.0001). However, there was no difference in weight between the 
three CR groups (Figure 1). 
The DIO group had the greatest percentage of body fat (mean body fat percentage 
= 52.02%) and was significantly greater than Control (mean body fat percentage = 
24.73%) and the three CR groups (mean HCCR = 13.91%, mean LCCR = 15.91%, mean 
IER = 11.49%) (all p values less than 0.0001). The HCCR, LCCR, and IER had 
significantly less body fat than Control (p = 0.0002, p = 0.0029, p < 0.0001, 
respectively). However, the three CR groups did not differ significantly in body fat 
percentage from each other (Figure 2a)  
Following the trend for weight and body fat percentage, the DIO group’s VWAT 
weighed significantly more than Control (p < 0.0001), as well as the three CR groups (all 
p values < 0.0001). Control did not differ significantly from the three CR groups (Figure 
2b).  
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Figure 1. Weekly body weights for all groups up to week 27. Different letters indicate 
significant differences, p < 0.05. 
2a. 2b.  
Figure 2. Body fat percentage (a) and VWAT weight (b) at time of necropsy. Different 
letters indicate significant differences, p < 0.05. 
 
Tumor progression and invasion, final tumor volume, and final tumor weight: 
The DIO group progressed significantly faster compared to Control and the CR 
groups and the DIO tumors were estimated to be significantly larger when palpated at 
three weeks after tumor injection (p < 0.0001). Control was significantly larger than 
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HCCR (p = 0.0414) and IER (p = 0.0268), but not different from LCCR at this time 
point. However, the three CR groups were not significantly different from each other 
(Figure 3). 
 At the time of necropsy, incidence of tumor body wall invasion was assessed. 
Control had a similar incidence of tumor body wall invasion (64.286%) compared to DIO 
(60%). However, the CR groups had a much lower incidence of tumor body wall invasion 
(HCCR: 14.286%, LCCR: 6.667%, IER: 6.667%) than both Control and DIO (data not 
shown). 
  
Figure 3. Tumor growth since injection of E0771 cells at week 25. Different letters 
indicate significant differences, p < 0.05. 
 
DIO, on average, had significantly greater tumor volumes and weight than 
Control (p = 0.0002 and p < 0.0001, respectively) and the three CR groups (all p values < 
0.0001). Tumor volume and weight in the Control group were significantly different from 
HCCR (p = 0.0326 and p = 0.0092, respectively) and IER (p = 0.0233 and p = 0.0106, 
respectively) but not from LCCR. The three CR groups did not differ from each other in 
final tumor volume or weight (Figure 4). 
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4a. 4b. 
	  
Figure 4: Final tumor volume (a) and final tumor weight (b) at time of necropsy. 
Different letters indicate significant differences, p < 0.05. 
 
Serum IL-6, Hormones and Adipokines analysis:  
 DIO had higher serum levels of IL-6 than Control (p = 0.0007), HCCR (p = 
0.0026), LCCR (p = 0.0086), and IER (p = 0.0157). Control did not have significantly 
different IL-6 levels than the three CR groups and nor did the three CR groups differ 
from each other (Figure 5).  
 
Figure 5: Serum IL-6 levels. Different letters indicate significant differences, p < 0.05. 
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Control, DIO, and HCCR serum adiponectin levels did not differ significantly 
from each other. However, Control differed from LCCR (p = 0.0292) and IER (p = 
0.0061). DIO did not significantly differ from LCCR but had significantly lower 
adiponectin levels than IER (p = 0.0292). There were no significant differences between 
the three CR groups (Figure 6a)  
DIO serum leptin levels were significantly greater than Control and the CR 
groups (all p value < 0.0001). However, Control and the three CR groups did not 
significantly differ from each other in serum leptin (Figure 6b).  
6a. 6b. 
 
Figure 6: Serum adiponectin levels (a) and serum leptin levels (b). Different letters 
indicate significant differences, p < 0.05. 
 
DIO serum insulin levels were significantly greater than Control (p = 0.0221), 
HCCR (p = 0.0201), LCCR (p = 0.0019), and IER (p = 0.008). However, Control did not 
significantly differ from the three CR groups (Figure 7a). Additionally, DIO serum IGF-1 
levels were significantly greater than Control (p = 0.0057) and the CR groups (p value < 
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0.0001). However, Control and the three CR groups did not significantly differ from each 
other in serum IGF-1 (Figure 7b).  
7a.       7b. 
 
Figure 7: Serum insulin levels (a) and serum IGF-1 levels (b). Different letters indicate 
significant differences, p < 0.05. 
 
DIO had significantly greater serum levels of resistin than HCCR (p = 0.0132), 
LCCR (p = 0.0051), and IER (p = 0.0030), however DIO did not differ significantly from 
Control. Additionally, Control levels were not significantly different from the three CR 
groups in serum resistin (data not shown).  
DIO GIP levels were significantly greater than Control (p = 0.0012), HCCR (p = 
0.0171), LCCR (p = 0.0036), and IER (p = 0.0123) groups. The three CR groups did not 
significantly differ from each other and did not differ from Control in serum GIP levels 
(Figure 8)  
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Figure 8: Serum GIP levels. Different letters indicate significant differences, p < 0.05. 
 
Mammary Fat Pad cytokine analysis: 
DIO had significantly greater IL-6 cytokine expression in the 9th MFP (distal to 
tumor) when compared to Control (p = 0.0204), HCCR (p = 0.0018), LCCR (p = 0.0129), 
and IER (p = 0.0009). However, there was no significant difference in IL-6 gene 
expression between Control and the three CR groups (Figure 9a).  
DIO had significantly greater TNF-α expression in the 9th MFP (distal to tumor) 
when compared to HCCR (p = 0.0002), LCCR (p = 0.004), and IER (p = 0.0021). 
However, DIO and Control TNF-α levels did not significantly differ from each other and 
nor did Control differ significantly from the three CR groups. The three CR groups did 
not differ from each other in relative TNF-α expression (Figure 9b). 
DIO had significantly greater IL-1β expression in the 9th MFP (distal to tumor) 
when compared to Control (p = 0.0112), HCCR (p = 0.0001), and IER (p = 0.0002). 
However there was no difference in DIO and LCCR IL-1β expression. As well, Control 
did not differ significantly from the three CR groups and nor did the CR groups differ 
significantly from each other (Figure 9c).  
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DIO had significantly lower IL-10 cytokine expression in the 9th MFP (distal to 
tumor) when compared to Control (p = 0.0055) and HCCR (p = 0.0193). There was no 
significant difference in IL-10 gene expression between Control and the three CR groups. 
DIO did not significantly differ in IL-10 expression from LCCR, and IER. Lastly, the 
three CR groups did not differ from each other in relative IL-10 expression (Figure 9d).  
9a. 9b. 
  
9c. 9d. 
  
Figures 9. Relative IL-6 (a), TNF-α (b), IL-1β (c), and IL-10 (d) expression in the 9th 
mammary fat pad. Different letters indicate significant differences, p < 0.05. 
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Tight Junction Proteins, Occludin, and Serum LPS:  
There were no significant differences between the five groups in the relative gene 
expression of ZO-1 in the colon (data not shown). 
Control had greater occludin expression in the colon than DIO (p = 0.0258), 
HCCR (p = 0.0002), and IER (p = 0.0081). Control did not differ significantly from 
LCCR and nor did DIO differ significantly from HCCR and IER. The three CR groups 
did not significantly differ from each other in relative occluding expression (Figure 10a).  
Control serum LPS levels were significantly lower than DIO (p < 0.0001), HCCR 
(p = 0.0033), and IER (p = 0.0331). However, there was no significant difference in LPS 
levels between Control and LCCR. DIO LPS levels were significantly greater than LCCR 
(p = 0.0032) but were not significantly different from HCCR, or IER. The three CR 
groups did not differ from each other in serum LPS (Figure 10b).  
10a. 10b. 
 
Figure 10: Relative mRNA occludin expression (a) in colon tissue and serum LPS (b). 
Different letters indicate significant differences, p < 0.05. 
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Discussion 
 The purpose of this study was to determine the effects of obesity and obesity-
reversing energy restricted diets on breast cancer development and the gut 
microenvironment. Our study replicated some known diet effects. For example, our DIO 
model exhibited known characteristics of obesity33, such as: significantly greater body 
weights, greater body fat percentages, greater average VWAT weight, higher serum GIP, 
hyperinsulinemia, and hyperleptinemia. Additionally, our CR groups displayed known 
CR characteristics, such as a reduction in mammary tumor growth in rodent models34,35. 
HCCR has previously been shown to reduce body weight and serum levels of metabolic 
hormones such as leptin, insulin, and IGF-136. LCCR has also been shown to reduce body 
weight, serum insulin levels, and serum IGF-1 levels, and increase serum adiponectin 
levels36,37. Lastly, IER diets have also been shown to reduce serum insulin levels and 
body fat30. Our study design not only replicated known diet effects but also allowed for 
concurrent comparison of the effects of several diet interventions, in one novel study 
design.  
 Overall, we observed that obesity resulted in dysfunctional perturbations in serum 
metabolic hormone levels and enhanced severity of tumor outcomes. Significant reversal 
of DIO effects on serum metabolic hormones and adipokines, such as IGF-1, leptin, GIP, 
resistin, and insulin, was achieved with all three CR diets. The CR groups improved 
Control and DIO’s serum adiponectin levels by increasing them. The three CR groups 
also reduced tumor volume, tumor weight, and tumor invasiveness. Our results also 
showed that DIO induced a pro-inflammatory local environment in the MFP by 
stimulating increased expression of pro-inflammatory cytokines38,39(i.e. IL-6, TNF-α, IL-
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1β) and decreased expression of the anti-inflammatory cytokine IL-1040,41. The three CR 
diets appear to have reversed this inflammation to some degree. Since there were few 
significant differences amongst the three CR groups in the reversal of hormonal secretion 
and inflammation, we concluded that macronutrient composition of the weight loss diet 
may not be important.  
We also observed that DIO induced significant changes in the gut such as a 
reduction in the mRNA expression of occludin. However, the three CR diets did not 
reverse this change. Conversely, there were no significant differences in ZO-1 (tight 
junction protein) mRNA expression between any of the groups. Occludin is critical for 
the regulation of tight junction proteins, for maintenance of the integrity of these proteins, 
and for preventing paracellular permeability of the gut epithelium. It has been noted with 
increasing evidence that absence of occludin in gut epithelium does not prevent the 
formation of tight junctions proteins but does increase permeability42,43. With our 
observations, we concluded that the effects of obesity on occludin expression may not be 
easily reversed by weight loss. 
Serum LPS levels were higher in those groups that had lower expression of 
occludin (i.e. DIO, HCCR, LCCR, IER), providing further support that occludin is 
necessary for maintaining gut integrity and for preventing the translocation of LPS from 
the gut lumen to blood. Despite the evidence that supports LPS as strong initiator for 
inflammation, in this study, increased serum LPS in the CR groups did not appear to 
promote increased systemic or local MFP inflammation. This suggests that elevated 
serum LPS levels may not play a major role in promoting systemic or local inflammation, 
which can enhance breast cancer development.  
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In our model, the dysfunctional hormone levels could be a potential mechanism 
for how obesity enhances tumor development. Since GIP is known to be an “obesity 
hormone”, facilitating the accumulation of triacylglycerol into adipose tissue44,45, this 
additional adipose seen with increased GIP levels could also promote a pro-inflammatory 
environment characteristic in obesity and cancer. The dysregulation of IGF-1 secretion 
seen under obeseogenic conditions has been found to increase the risk and development 
of breast cancer46, especially in pre-menopausal women. The increased secretion of IGF-
1 observed in this study, together with the inflammatory environment induced by obesity 
may lead to tumor promotion. Therefore, CR diets may be more effective in reversing 
systemic hormonal perturbations, and may result in a greater/more effective reduction in 
the severity of breast cancer than control diets.  
The increased local MFP inflammation seen in our study may be another 
mechanism by which obesity enhances the severity of tumor development. The increased 
IL-6, TNF-α, and IL-1β and decreased IL-10 observed in our study indicates the tumor-
promoting effects of obesity. While the reversal of these cytokine levels by CR diets may 
result in a more effective reduction of breast cancer severity.  
 Although sample analysis is still ongoing, from our data thus far we have shown 
that CR is effective in reversing systemic hormonal changes and local inflammation 
induced by obesity. However, the CR diets may not be effective in reversing obesity-
induced changes in the gut because of the persistant lower occludin levels and higher 
serum LPS. Further analysis and rRNA sequencing of the stool collected is needed to 
clarify the extent of gut microenvironment changes induced by diet type. Additional 
 26 
studies are needed to determine whether there is a relationship between CR diet 
composition, breast cancer development, and the gut microenvironment 
 
Conclusion 
Based on our results, we can conclude that calorie restricted diets, of varying 
macronutrient composition and schedule, effectively reverse the mammary tumor 
promoting effects of chronic obesity.  
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